Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 5/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20523496 | 0.96 | — | — | |
| SCHEMBL30338212 | 0.96 | CXCR4 (0.69) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL27902303 | 0.96 | CXCR4 (0.69) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| Piperazine SCHEMBL28322579 | 0.96 | CXCR4 (0.67) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL796635 | 0.96 | — | — | |
| SCHEMBL22582300 | 0.96 | CXCR4 (0.67) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL1894089 | 0.88 | CXCR4 (0.57) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL18279383 | 0.88 | — | — | |
| SCHEMBL9947670 | 0.87 | CXCR4 (1.00) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL577659 | 0.87 | CXCR4 (1.00) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110023796-A | Wavelength convert component and back light unit | 富士胶片株式会社 | 2019-07-16 | — | — | CN | disclosed |
| CN-108699299-A | Polyolefin resin composite and polyolefin-based resins film | 住友精化株式会社 | 2018-10-23 | — | — | CN | disclosed |
| CN-108350309-A | Aqueous resin coating composition, heat-ray shielding film using same, and method for producing same | 株式会社ADEKA | 2018-07-31 | — | — | CN | disclosed |
| CN-105705570-B | Coated substrate having improved coating properties | 株式会社艾迪科 | 2018-05-15 | — | — | CN | disclosed |
| CN-107250256-A | Vinyl chloride resin composition | 株式会社艾迪科 | 2017-10-13 | — | — | CN | disclosed |
| EP-2412729-A2 | Peptide purification by means of hard metal ion affinity chromatography | Novo Nordisk A/S (DK) | 2012-02-01 | — | — | EP | disclosed |
| EP-2399938-A2 | Peptide purification by means of hard metal ion affinity chromatography | Novo Nordisk A/S (DK) | 2011-12-28 | — | — | EP | disclosed |
| US-20090143529-A1 | Peptide purification by means of hard metal ion affinity chromatography | HEARN MILTON THOMAS WILLIAM | 2009-06-04 | — | — | US | disclosed |
| EP-1758677-A2 | PEPTIDE PURIFICATION BY MEANS OF HARD METAL ION AFFINITY CHROMATOGRAPHY | NOVO NORDISK A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005120700-A2 | PEPTIDE PURIFICATION BY MEANS OF HARD METAL ION AFFINITY CHROMATOGRAPHY | NOVO NORDISK A/S (DK) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143529-A1 | Peptide purification by means of hard metal ion affinity chromatography | MAX, PTMS, SLC7A1 | CXCR4 1801/4885SMN1; SMN2 3612/4885HIF1A 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.